Biomarker Panel for Classification of Renal Cell Carcinoma
miRNA SSNA in situ Hybridization System

Renal cell carcinoma (RCC) consists of an array of morphologically and genetically distinct tumors, the most prevalent of which are clear cell renal cell carcinoma (ccRCC), papillary RCC (pRCC) and chromophobe RCC (chRCC). Accurate distinction between the RCC subtypes poses a challenge for pathologists, as they share a wide range of common features and has overlapping immunohistochemical profiles. Subtypes also have different survival outcomes and responses to therapy. Although surgical resection remains the gold standard treatment for RCC, long-term complications, morbidity and mortality of RCC are difficult to accurately predict. Also, the current approaches to chemotherapy and radiotherapy have only limited efficacy on RCC. Therefore, accurate classification of RCC is critical for clinical decision making. Accumulating evidence has reported microRNAs (miRNAs) as promising biomarkers for early cancer detection, accurate prognosis, as well as molecular targets for cancer treatment. Aberrant expression of miRNAs has been reported to be associated with progression of renal cancer. Evaluation of miRNA profiles in RCC holds promise for improving understanding of pathogenesis and therapeutic outcome.

BioGenex is pleased to launch four Super Sensitive Nucleic Acid microRNA in situ hybridization (SSNA miRNA ISH) probes and automated systems for classification of RCC subtypes. Molecular differentiation using the miRNA probes have demonstrated promising results in subclassifying the most common RCC subtypes including renal oncocytomas.

miRNA ISH was performed on 98 formalin-fixed, paraffin-embedded (FFPE) RCC tissues consisting of 37 ccRCC, 28 pRCC, 20 chRCC and 13 oncocytoma cases. miRNA ISH using BioGenex RCC probes demonstrated significant upregulation of miR-126 and miR-222 in ccRCC than pRCC tumor; while miR-222 was non-significantly expressed among the two RCC subtypes. Significant nuclear expression (upregulation) was also reported with miR-200b and miR200C in chRCC compared with oncocytoma cases; while miR-222 was non-significantly expressed. By utilizing the BioGenex product line of miRNA ISH probes and automated Xmatrx® staining, clinical diagnosis time and reliability are significantly improved to better serve patients.

More information on our miRNA products! 

Please click on below links to download Renal Cell Carcinoma Classification Biomarker Panel and Application Note.

BioGenex also has an extensive catalog of 235 unique miRNA probes

BioGenex miRNA Probes for Renal Cell Carcinoma Classification